Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
42 hedge funds and large institutions have $86.3M invested in Genocea Biosciences, Inc. in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 5 closing their positions.
993% more call options, than puts
Call options by funds: $4.26M | Put options by funds: $390K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
12% more capital invested
Capital invested by funds: $77M → $86.3M (+$9.32M)
8% more funds holding
Funds holding: 39 → 42 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$3.27M |
| 2 |
Two Sigma Advisers
New York
|
+$574K |
| 3 |
Millennium Management
New York
|
+$296K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$233K |
| 5 |
Two Sigma Investments
New York
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$2.68M |
| 2 |
Renaissance Technologies
New York
|
-$1.1M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$429K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$148K |
| 5 |
Capstone Investment Advisors
New York
|
-$67K |
GNCA Hedge Fund Activity: Q1 2021 in Review
42 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2021, worth a combined $86.3M — up 12% from $77M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GNCA positions and 5 closed out — a net gain of 3 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Commodore Capital, adding an estimated $3.27M. The largest seller was Bank of America, cutting an estimated $2.68M.
- 42 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2021, up from 39 in Q4 2020.
- Funds reported $86.3M of Genocea Biosciences, Inc. stock for Q1 2021, up 12% quarter-over-quarter.
- 8 funds opened new Genocea Biosciences, Inc. positions in Q1 2021 and 5 closed out, a net change of +3 holders.
- The largest Genocea Biosciences, Inc. buyer in Q1 2021 was Commodore Capital, an estimated $3.27M added.
- The largest Genocea Biosciences, Inc. seller in Q1 2021 was Bank of America, an estimated $2.68M sold.
Based on aggregated 13F filings for Q1 2021.